https://psoriasis-hub.com

Home | PsOPsA Hubin partnership with the Federation of Clinical Immunology Societies (FOCiS).Home | PsOPsA Hub  TRANSLATEThe pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.Steering committeeAbout usNewsletterContactOur hubsLOGIN MY pso HUBMY BOOKMARKED CONTENTACCOUNT SETTINGSLOG OUTYou're logged in! Click here any time to manage your account or log out.Brought to you by The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.Disease AreasTherapeuticsCongressesTrialsExpert OpinionsDrug UpdatesEducational ResourcesView allNow you can support HCPs in making informed decisions for their patientsYour contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.Make a one-off contributionMake a repeat contributionFind out moreMyCreate an account and access these new features:Bookmark content to read laterSelect your specific areas of interestView pso content recommended for youFirst, please enter your email address to sign in or create your account.Your email addressThe personal information collected is utilized for the purposes defined within the privacy policy. We do not share your information with any third parties.CONTINUERelationship between skin severity and PASDAS in PsA: A cross-sectional study in the BSR-PsA and GRACE cohortsWe summarize key findings from a cross-sectional study exploring the relationship between skin severity and PASDAS in PsA, published by Mulder et al. in Rheumatology.May 16, 2025Predictive factors of early super-response in patients with psoriasis treated with bimekizumabA retrospective study examined the efficacy and safety of bimekizumab in 109 patients with plaque psoriasis in Ita...May 12, 2025|BimekizumabSERENA: 3-year interim analysis of secukinumab in Greek patients with PsA and ankylosing spondylitisWe summarize key findings of the 3-year interim analysis from the SERENA study evaluating long-term retention ...May 9, 2025Guselkumab long-term real-world safety: Results from the EARLY studyMortato et al. published findings in Clinical and Experimental Dermatology from a real-world, longitudinal study, which assessed the long-term...May 2, 2025|GuselkumabPaolo Gisondi"The Hub is an innovative and valuable tool for healthcare professionals, providing valuable, up-to-date information on the most exciting advances in these areas through expert opinions and case studies - Paolo Gisondi"Featured Expert OpinionEditorial theme | How to select treatments based on patient ​and disease characteristics?  Laura Coates discusses the complications of selecting the correct treatment when there are multiple options available. Oct 6, 2023Recent content VIEW ALL The impact of stigmatization and social interactions on patients with psoriasisPsoriasis is associated with a significant psychological impact on patients, with frequent reports of stigmatization. A study was c...Apr 28, 2025Safety and efficacy of adalimumab interchangeability with CT-P17 adalimumab biosimilar: Results from the OLE of a phase III studyUse of biosimilars can potentially allow for a greater number of patients to rece...Apr 23, 2025|AdalimumabBrodalumab in plaque psoriasis: A Canadian real-world retrospective analysisWe summarize key findings from a Canadian real-world retrospective analysis evaluating the effectiveness of brodalumab in plaque psori...Apr 16, 2025|Plaque psoriasisImpact of fatigue and musculoskeletal pain on QoL in pediatric patients with psoriasisWe summarize key findings from an observational study assessing the impact of musculoskeletal pain and fatigue on QoL in ped...Apr 9, 2025|Pediatric psoriasisMost readUpdated GRAPPA treatment guidelines for psoriatic arthritisThe Good Care Campaign aims to raise awareness for treatment of psoriatic arthritis, including patients with comorbidities and difficult-to-treat popul...Jun 23, 2023Spotlight on the VISIBLE trial in people of colorWe share a presentation by Andrew Alexis and Mona Shahriari that explored the study design, unique approach, and outcomes from the VISIBLE trial in people of col...Mar 5, 2025SERENA: 3-year interim analysis of secukinumab in Greek patients with PsA and ankylosing spondylitisWe summarize key findings of the 3-year interim analysis from the SERENA study evaluating long-term retention ...May 9, 2025Approved and investigational JAK inhibitors for psoriatic arthritisIn recent years, several JAK inhibitors have been approved for the treatment of patients with active PsA. Here, we summarize the current and pi...Jun 8, 2023PsoriasisAdd to areas of interest VIEW ALL Predictive factors of early super-response in patients with psoriasis treated with bimekizumabA retrospective study examined the efficacy and safety of bimekizumab in 109 patients with plaque psoriasis in Ita...May 12, 2025|BimekizumabGuselkumab long-term real-world safety: Results from the EARLY studyMortato et al. published findings in Clinical and Experimental Dermatology from a real-world, longitudinal study, which assessed the long-term...May 2, 2025|GuselkumabThe impact of stigmatization and social interactions on patients with psoriasisPsoriasis is associated with a significant psychological impact on patients, with frequent reports of stigmatization. A study was c...Apr 28, 2025Safety and efficacy of adalimumab interchangeability with CT-P17 adalimumab biosimilar: Results from the OLE of a phase III studyUse of biosimilars can potentially allow for a greater number of patients to rece...Apr 23, 2025|AdalimumabPsoriatic arthritisAdd to areas of interest VIEW ALL Relationship between skin severity and PASDAS in PsA: A cross-sectional study in the BSR-PsA and GRACE cohortsWe summarize key findings from a cross-sectional study exploring the relationship between skin sever...May 16, 2025SERENA: 3-year interim analysis of secukinumab in Greek patients with PsA and ankylosing spondylitisWe summarize key findings of the 3-year interim analysis from the SERENA study evaluating long-term retention ...May 9, 2025Ixekizumab post-marketing surveillance in Japanese patients with psoriasis and PsATorii et al. conducted a post-marketing surveillance study to address clinical questions regarding the long-term use of ixekizum...Apr 4, 2025|IxekizumabConsensus recommendations for the management of pediatric psoriasis from the Spanish AEDVNew recommendations from the Spanish AEDV, published by Vicente et al., aim to act as a guidance tool for dermatologists ...Apr 2, 2025|Pediatric psoriasisDrug Updates VIEW ALL Important announcement🚨 News 🚨The has designated ustekinumab-aauz biosimilar as interchangeable with its reference product, ustekinumab, for all its indications...May 21, 2025Important announcement🚨 NEWS 🚨 A phase III trial of piclidenoson, an A3AR agonist, has been initiated according to the FDA- and EMA-approved protocol. Patients ...Mar 26, 2025Important announcement🚨 NEWS 🚨 The biosimilar ustekinumab-ttwe is now available in the US in pre-filled syringes, intravenous infusion single-dose vials, and su...Feb 24, 2025Important announcement🚨 NEWS 🚨 The has approved ustekinumab-stba, an ustekinumab biosimilar, for the treatment of plaque and in adult and pediatric patients. Re...Dec 19, 2024Brought to you byDelivering streamlined independent medical education to enhance clinical practiceIn partnership withThe PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters.We would like to express our gratitude to the following companies for their support:UCB: For website development, launch, and ongoing maintenance.UCB: For educational content and news updates.Terms and ConditionsCookie PolicyPrivacy PolicyNewsletter© PsOPsA Hub 2025. All rights reserved.All content on this site is intended for healthcare professionals only.enenhttps://psoriasis-hub.com

Fa'atonu lau saite?

O au mea na e fai?